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airflow limitation and pulmonary inflammation.
Inhaled corticosteroids (ICS) have been shown to be effective in the reduction of
the number of exacerbations and the rate of deterioration in health status in
patients with more advanced chronic obstructive pulmonary disease (COPD).
Therefore current international guidelines recommend ICS for patients with severe
COPD (FEV1o50%) with at least one exacerbation within the last year.
We determined the short-term effect of the inhaled corticosteroid beclometha-
sone in HFA 134 formulation (Ventolairs) on Health related Quality of Life (HRQOL),
pulmonary function and the release of the cytokines Interleukin-10 (IL-10),
Granulocyte-Macrophage Colony-stimulating Factor (GM-CSF), Interferon-g (IFN-g)
and Macrophage Inflammatory Protein-1a (MIP-1a) from peripheral blood monocytes
of patients with COPD (n ¼ 11) in a 12 week double blind cross over placebo-
controlled study.
Baseline lung function and the St. George Respiratory Questionnaire (SGRQ) were
performed at the start and the end of each treatment phase. Monocytes were
separated from blood at the end of each treatment phase.
The treatment with Ventolairs resulted in an increase of PEF from 4.92 to 5.53 l/s
and a decrease of RV% TLC (% predicted) values from 144.52 to 131.36. Inhaled HFA
beclomethasone did not affect the cytokine release of IL-10, IFN-g, GM-CSF and MIP-
1a. All cytokines were measured using commercially available Enzyme Linked
Immun Sorbent Assay (ELISA) kits. The symptom score of the St. George Res-
piratory Questionnaire significantly decreased from 55.12 to 47.77 units in the
active period compared to the placebo period after the treatment with HFA
beclomethasone.Elsevier Ltd. All rights reserved.
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Effects of inhaled HFA beclomethasone on pulmonary function 1419The present study shows that a short-term treatment with inhaled steroid
beclomethasone in fine particle HFA formulation decreases the hyperinflation and
improves the PEF and the COPD symptoms.
& 2005 Elsevier Ltd. All rights reserved.Table 1 Demographic characteristics of COPD
patients and normal controls.Introduction
Chronic obstructive pulmonary disease is an in-
flammatory disorder of the airways characterized
by infiltration of the airways with inflammatory
cells such as neutrophils and involvement of
cytokines and other inflammatory mediators. The
clinical feature is a progressive airflow limitation
with a poor reversibility and a rapid decline in
health status.1
First line treatment encompasses b2-agonists and
anticholinergics for symptom relief and reduction
of hyperinflation. These substances act solely as
bronchodilators and have minimal anti inflamma-
tory effects.2
Although therapy with inhaled corticosteroids is
still controversial they have been shown to be
effective in the amelioration of respiratory symp-
toms and exacerbations as well as health related
quality of life. A recent study demonstrated that
discontinuation of ICS in stable COPD patients leads
to a higher recurrence-risk of exacerbations and a
significant deterioration in aspects of health re-
lated quality of life.3
Many trials demonstrated that a treatment with
inhaled steroids reduces the number and frequency
of exacerbations and mortality.4–9 Therefore cur-
rent international guidelines recommend ICS for
patients with severe COPD (FEV1o50%) with at
least one exacerbation per year that required
therapy with antibiotics or oral steroids.10,11
All beneficial effects of ICS have been demon-
strated in long-term treatment studies. However
little is known about short-term anti-inflammatory
effects of inhaled steroids in patients with COPD.
Therefore the present double-blind, cross over study
aims to investigate the short-term effects of beclo-
methasone in HFA 134 formulation on Health Related
Quality of Life, pulmonary function and inflammatory
parameters of subjects with COPD in a 12 week
double blind placebo controlled crossover study.COPD
patients
Normal
controls
Age 61.8273.50 51.3672.31
Gender (m/f) 7/4 3/8
Smoking history
(packyears)
41.6476.42 11.9173.86
Allergy status No NoMethods
Patients
Eleven patients with COPD (age 61.8273.50 years,
4 female, 7 male) diagnosed according to AmericanThoracic Society guidelines were enrolled. All
patients showed an FEV1 reversibility of less than
9% in response to inhaled bronchodilators. Out of
this population 5 were smokers, 3 were ex smokers
and 3 were non-smokers (45 years of smoking
cessation). Grading the disease severity revealed
that 5 patients had mild and 6 patients had
moderate COPD according to the 2004 updated
GOLD guidelines.11 At time of investigation, all
patients were clinically stable without signs of
acute exacerbation. No patient had required
hospital admission or treatment change during the
preceding 3 months. None of the patients received
inhaled or oral corticosteroids during the preceding
8 weeks. Treatment included only short acting b2
agonists or theophylline for symptom relief. Exclu-
sion criteria were current or past diagnosis of
asthma and a respiratory tract infection in the
previous 2 weeks. Patients with cancer, thyroid
disease, severe liver disease and chronic heart
failure were also excluded.
For comparison 11 healthy control subjects of
similar age and gender distribution were recruited.
The control group did not receive beclomethasone
treatment (Table 1).Study design
The study was a 28 week double-blind randomized
cross-over study comparing the effects of the
inhaled glucocorticosteroid beclomethasone in
HFA 134 formulation (400 mg twice daily) via a
multidose Autohaler (IVAX, Neuss, Germany) with
that of a matched placebo. The dose of inhaled
steroid was chosen in a medium range in order to
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Figure 1 Schematic diagram of study design.
M. John et al.1420observe an effect on the inflammatory parameters
and quality of life without an increased risk of side
effects such as adrenal suppression.
Either steroid or placebo treatment was given for
12 weeks, separated by a 4 week washout period.
Patients documented their peak flow rates twice
daily, symptom score according to St. Georges
Questionnaire of Life (SGRQ) and medication
usage.12–14
Pulmonary function tests were performed at day
1, 84, 112 and 196 (Fig. 1).
The study was approved by the Ethics Committee
of the University Hospital Charite´ and all patients
gave their written informed consent.Materials
Complete culture medium containing RPMI-1640
(Sigma, Germany), 10% heat-inactivated fetal calf
serum (Gibco, Germany) 2mM L-glutamine and
penicillin–streptomycin both from Sigma was used.
Culture plates were from Falcon (Germany).
Isolation of peripheral blood monocytes
The method has been described previously.15
Briefly, peripheral venous blood was mixed with
acid-citrate (1:6 vol/vol) and sedimented with
dextran for 60min. Mononuclear cells were sepa-
rated by Ficoll-Hypaque and plated after Hanks
Balance Salt Solution (HBSS) washing in 24 well
plates at a concentration of 1 106 monocytes.
After stimulation with IL-1b (10 ng/ml) or Lipopo-
lysaccharide (LPS) (1 mg/ml) for 24 h cell culture
supernatants were harvested for cytokine measure-
ment.
Enzyme- linked immunosorbant assays for IL-
10, IFN-g, MIP-1a and GM-CSF
These cytokines were assayed using a quantitative
sandwich enzyme immunoassay technique. For allcytokines, commercially available kits were used
(Quantikine, R&D Systems, Wiesbaden, Germany).
Briefly, monoclonal anti-cytokine antibody was
coated onto a microtitre plate, to which standards
and samples were added. An enzyme-linked poly-
clonal antibody specific for MIP-1a, IFN-g, GM-CSF
and IL-10 was added to the wells to sandwich-
immobilize the cytokine proteins. Addition of a
stabilized chromogen and hydrogen peroxide al-
lowed a colour development in proportion to the
amount of MIP-1a, IFN-g, GM-CSF and IL-10 assayed
by measurement of optical density using a spectro-
photometer set to 450 nm. The lower limit of
detection was 8 pg/ml for IFN-g, 10 pg/ml for MIP-
1a, 3 pg/ml for GM-CSF and 3.9 pg/ml for IL-10,
respectively.Assessment of health-related-quality of life
The SGRQ is designed to measure health impair-
ment in patients with asthma and COPD. In both
placebo and active period patients documented
their quality of life using the SGRQ.12–14 Briefly, this
scoring system is a valid method to measure the
quality of life. Using different sections such as
symptoms, activities and impacts a comprehensive
assessment of health-related-quality of life can be
obtained.
A score for each of the three sections as
well as a total score for overall quality of
life can be calculated. Scores range from 0 to
100, higher scores correlate with a poorer quality
of life.
For the judgement of treatment efficacy in SGRQ
score an improvement of 4.3 units in quality of life
was considered to be significant.13,14Data analysis
Results are given as mean7standard error of
mean (SEM). For the statistical analysis the absolute
values of cytokine measurements, of the sections of
the SGRQ and the pulmonary function were
considered. Data obtained within the patient
groups (between the two treatment periods) were
compared using Wilcoxon’s signed rank test. For the
inter-group comparison (between COPD patients
and healthy controls) the. Mann–Whitney Test was
used. A P-value of o0.05 was considered to be
significant.
The statistical analysis was performed with
StatView 4.5 (Abacus Concepts Inc., Berkley, CA,
USA).
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Effect of HFA 134 beclomethasone on
pulmonary function
There was no significant difference in FEV1, PEF and
RV% TLC (%predicted values) between the start and
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Figure 2 Effect of inhaled HFA-beclomethasone on RV%
TLC (% predicted) (panel A) and PEF (panel B) in 11 COPD-
patients at entry and after 12 weeks placebo period and
at entry and following 12 weeks HFA-beclomethasone
treatment. Open bar shows the end of the placebo
period, solid bar shows the end of the HFA-beclometha-
sone treatment period and the hatched bar represents
normal controls (n ¼ 10 for RV% TLC (% predicted), n ¼
11 for PEF). *Po0:05, active was compared to placebo,
controls were compared to both active and placebo.mean PEF improved from 4.93 to 5.53 l and RV% TLC
(%predicted values), a marker of hyperinflation
decreased from 144.52 to 131.36 after 12 weeks of
steroid treatment (Po0:05) (Fig. 2).
FEV1 remained unchanged in the steroid treat-
ment period.
Compared to normal controls in both active and
placebo period the pulmonary function was im-
paired (Table 2).Effects of HFA 134 beclomethasone on
quality of life assessed with the St. George
questionnaire of life
The symptom score significantly decreased from
55.14 to 47.76 units in the active compared to the
placebo period after the treatment with HFA
beclomethasone.
In the total quality of life score a slight but not
significant decrease was detected following beclo-
methasone treatment.
The activity score and the impact score were not
affected. (Table 3)Effects of HFA 134 beclomethasone on
cytokine release from peripheral blood
monocytes
Inhaled HFA beclomethasone did not affect the
cytokine release of IL-10, GM-CSF and MIP-1a.
There was no significant difference between the
placebo and the beclomethasone treatment at
baseline and after 24 h stimulation with LPS and
IL-1b.
IFNg was not detectable in the majority of
monocyte supernatants of COPD-patients and nor-
mal subjects.
The IL-10 and GM-CSF release in both active and
placebo treatment periods was significantly higher
compared to normal controls as measured at
baseline (Fig. 3).Effects of HFA 134 beclomethasone on serum
cortisol levels
Serum cortisol level was measured at the end of
each treatment period.
Serum cortisol was not affected by the treatment
with inhaled HFA beclomethasone.
Normal subjects also presented a normal serum
cortisol level.
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Table 2 Pulmonary function of 11 COPD patients compared to normal controls.
Entry placebo End of placebo Entry active End of active Normal controls
VC (l) 2.8270.25 2.82 70.24 2.7770.25 2.8170.25 3.5670.25n¼11
VC %predicted 75.1572.32 75.3472.87 73.7172.79 74.873.37 96.473.94n¼11
FVC (l) 2.9370.26 2.8970.24 2.8070.24 2.9770.25 3.5770.26n¼11
FVC %predicted 80.8572.62 80.1273.46 77.6373.34 82.4373.41 99.9173.83n¼11
FEV1 (l) 1.8870.19 1.8270.19 1.8270.19 1.8970.18 3.0870.25n¼11
FEV1 %predicted 64.9773.93 62.9374.97 63.3774.94 65.9374.93 102.3974.46n¼11
FEV1 %VC 66.7172.99 64.1673.43 65.9673.52 67.9573.39 8671.54n¼11
FEV1 % VC %predicted 86.9673.81 83.7074.51 86.1874.91 88.6674.43 108.872.26n¼11
PEF (l/s) 5.1970.62 5.0470.67 4.9370.71 5.5370.66* 7.8870.85*n¼11
PEF %predicted 69.2675.79 67.9677.49 65.9378.07 74.5577.44 107.1876.89*n¼11
R tot (kPa*s/l) 0.4270.04 0.4870.07 0.4770.08 0.4570.08 0.2470.042n¼10
R tot %predicted 139.66713.99 159.40723.94 161.68728.20 148.93727.36 79.23714.19n¼10
RV (l) 3.3270.34 3.3770.30 3.5170.36 3.1370.32 2.2270.11n¼10
RV %predicted 149.35712.20 154.33715.57 160.83717.66 141.37712.69 119.777.37n¼10
TLC (l) 6.2570.49 6.2870.47 6.3370.51 6.1770.48 5.7870.33n¼10
TLC %predicted 101.5574.59 102.5675.19 103.0175.37 100.3974.31 103.7174.5n¼10
RV% TLC 52.5472.77 53.1872.85 54.8872.93 50.3573.05* 39.3571.82**n¼10
RV% TLC %predicted 137.1476.33 139.7578.51 144.5279.59 131.3677.70* 107.8674.75*n¼10
*Po 0.05; **Po 0.01.
Active was compared to placebo, controls were compared to both active and placebo.
Table 3 St. George respiratory questionnaire.
Entry placebo End of placebo Entry active End of active Normal controls
Symptom score 57.48 55.14 54.58 47.76 10.74
Activity score 62.86 58.81 58.97 57.65 0.57
Impact score 33.40 36.41 32.83 34.67 1.18
Total score 46.11 46.20 44.28 43.82 2.50
Scores range from 0 to 100, higher scores correlate with a poorer quality of life.
For the judgement of treatment efficacy in SGRQ score an improvement of 4.3 units in quality of life was considered to be
significant.13,14
44.3 units compared to end of placebo.
M. John et al.1422Discussion
The present study demonstrates that a short-term 3
month treatment with inhaled corticosteroid HFA
beclomethasone in mild to moderate COPD im-
proves pulmonary function by decreasing hyperin-
flation and reduces the pulmonary symptoms.
The role of inhaled corticosteroids in the
therapeutic management remains controver-
sial.16,17 Inhaled corticosteroids have been shown
to be ineffective in decreasing the accelerated
decline of pulmonary function in COPD patients as
has been demonstrated in major trials.3–8 Bene-
ficial effects of steroids are amelioration of
respiratory symptoms, decreased frequency and
severity of exacerbations and improvement ofhealth-related quality of life. Most of these trials
were carried out using chlorofluorocarbon (CFC)-
free-breath actuated inhalers for the delivery of
the corticosteroids. But mass output and particle
size distribution of drug aerosol delivered by the
different inhalation devices and possible therapeu-
tic effects on COPD outcome were not taken into
consideration.
This gave the background to investigate the
short-term effects of HFA 134 beclomethasone on
pulmonary function, HRQOL and molecular inflam-
matory parameters in patients with COPD.
The advantage of HFA 134 beclomethasone
formulation delivered by the Autohaler is the
distribution of small drug particles (1.1 mm) that
reach the small airways which represent the target
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Figure 3 Effects of inhaled HFA-beclomethasone on IL-10
(panel A) and GM-CSF (panel B) production from
peripheral blood monocytes of 11 COPD patients either
during placebo (open bar) or HFA-beclomethasone treat-
ment (solid bar) and in 11 normal subjects (hatched bar),
at baseline. *Po0:05 compared to placebo and active
period.
Effects of inhaled HFA beclomethasone on pulmonary function 1423for anti-inflammatory drugs. It has been shown that
the Autohaler is relatively independent from
inspiratory parameters and produces a constant
aerosol output with a high fraction of fine particles
compared to other devices.18
The serum cortisol levels were not affected by
inhaled HFA beclomethasone indicating that this
does not exhibit side effects in terms of adrenal
suppression.
Compared to normal controls monocytes from
COPD patients released more inflammatory cyto-kines (GM-CSF, IL-10) consistent with systemic
manifestation of the pulmonary inflammation.
Measurement of HRQOL using distinct question-
naires is an established method for assessing
therapeutic effects for patients with COPD. We
have used the SGRQ, that represents a valid and in
COPD trials widely accepted method for assessing
quality of life.13,14 The present study demonstrates
a reduction of the symptom score indicating that
inhaled HFA beclomethasone reduces COPD symp-
toms even following a short-term treatment
course.
There was no effect of HFA beclomethasone on
FEV1 which is not surprising since most of the COPD
trials demonstrated only moderate effects on FEV1.
The reduction of RV%/TLC as a marker of hyperin-
flation indicates that HFA beclomethasone im-
proves pulmonary function via reduction of
hyperinflation.
Taken together the present study shows that a
short-term treatment with inhaled steroid beclo-
methasone in fine particle HFA formulation leads to
an improvement of pulmonary function and reduc-
tion of COPD symptoms.
In conclusion, HFA beclomethasone delivered by
the Autohaler is a safe drug formulation with
beneficial effects in clinically stable COPD patients.References
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